Five Stocks Draw Attention After Earnings, Trial Results and Merck Deal

Major U.S. indices ended mixed on Monday, with the Dow Jones Industrial Average slipping 0.07% to 51,966.03, while the S&P 500 gained 0.41% to 7,690.73 and the Nasdaq climbed 1.11% to 26,430.89. These are the top stocks that gained the attention of retail traders and investors throughout the day. Amazon.com Inc.

(NASDAQ: AMZN ) Amazon closed 4.98% higher at $262.45 after reaching $263.72 intraday and touching $255.22. The stock’s 52-week range is $196 to $287.16. Morgan Stanley named Amazon a top pick and raised its price target to $350 from $335, citing expected AWS growth, margin expansion, Bedrock visibility, agentic shopping and robotics. Meanwhile, Amazon secured the right to buy up to $521 million in 3M shares as part of an expanded partnership tied to data-center product purchases, Reuters reported on Monday.

Read Also: GameStop CEO Ryan Cohen Warns Humans Could Attack Smarter Robots — ‘Whether That Ends Up Being World War III, I Don’t Know’ Cleveland-Cliffs Inc. (NYSE: CLF ) Cleveland-Cliffs gained 16.05% to close at $14.10, following an intraday high of $14.58 and low of $12.94. Its 52-week high is $16.70, while its low is $7.73. Cleveland-Cliffs reported third-quarter adjusted EPS of 28 cents, beating estimates of 19 cents, while revenue of $5.6 billion missed expectations of $5.7 billion and adjusted EBITDA reached $612 million.

The steelmaker projected fourth-quarter adjusted EBITDA of approximately $715 million and more than $4 billion in 2027, citing stronger steel prices, higher shipments and lower costs, while announcing plans to idle Stelco’s galvanizing lines amid Canadian oversupply. Disc Medicine Inc. (NASDAQ: IRON ) Disc Medicine surged 38.86% to $78.93, trading as high as $80.22 and as low as $69.98. The stock’s 52-week range spans $40 to $99.50.

In after-hours trading, the stock fell 1.43% to $77.80. The biotechnology company announced positive topline results from its APOLLO Phase 3 trial of bitopertin in erythropoietic protoporphyria and X-linked protoporphyria, conditions involving severe sunlight-related skin pain. Disc Medicine’s bitopertin met both co-primary and all secondary endpoints in the APOLLO trial, reducing whole-blood metal-free PPIX by 41.4% and increasing monthly pain-free light exposure by 12.2 hours, with statistically significant improvements in phototoxic reactions and quality of life.

The treatment was generally well tolerated, and the company planned to resubmit its FDA application by year-end, with a regulatory decision expected by mid-2027. Silence Therapeutics plc (NASDAQ: SLN ) Silence Therapeutics soared 125.58% to close at $19.58, reaching $19.61 at its intraday high and falling to $19.56 at its low. Its 52-week range is $4.19 to $19.61. Germany’s Merck agreed to acquire the biotechnology company for approximately $1.3 billion in cash.

The buyout announcement sent shares sharply higher, with volume reaching nearly 49 times its 100-day average. EyePoint Inc. (NASDAQ: EYPT ) EyePoint plunged 85.28% to close at 44 cents after reaching an intraday high of 60 cents and a low of 40 cents. Its 52-week high is $19.01, and its low is 40 cents.

EyePoint announced plans to cut 53% of its workforce and end its Phase 3 wet AMD trials early after DURAVYU failed to meet the primary visual acuity endpoint in the 475-patient LUCIA study. The restructuring was expected to save approximately $30 million annually as the company redirected its $118 million cash reserves toward DURAVYU’s diabetic macular edema program, with Phase 3 results expected in the fourth quarter of 2027. Edge Stock Rankings indicate Amazon stock has a Momentum score in the 68th percentile and a Value score in the 57th percentile.

See More: Top Value Stocks Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published editors. Photo Courtesy: fadil051922 on Shutterstock.com